MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies for cancer and other immune-mediated diseases. Its platform enables scalable, reproducible manufacturing for off-the-shelf delivery without requiring lymphodepletion or HLA matching, harnessing both innate cytotoxicity and adaptive immune memory. The lead product candidate, agenT-797, is an allogeneic native iNKT cell therapy currently in multiple Phase 1 clinical trials for solid tumors and other indications. The company is advancing a pipeline of engineered iNKT programs, including MiNK-413, an IL-15 armored CAR-iNKT targeting B cell maturation antigen for myeloma, and MiNK-215, an IL-15 armored program targeting fibroblast activation protein in tumor stroma. MiNK Therapeutics, Inc. emphasizes precision targeting through cell engineering and editing, positioning it as an innovator in next-generation cell therapies within the biotechnology sector. Incorporated in 2017 and headquartered in New York, New York, the company operates core segments in research, clinical development, and manufacturing of these immunotherapies.